CL2007003440A1 - Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida - Google Patents

Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida

Info

Publication number
CL2007003440A1
CL2007003440A1 CL200703440A CL2007003440A CL2007003440A1 CL 2007003440 A1 CL2007003440 A1 CL 2007003440A1 CL 200703440 A CL200703440 A CL 200703440A CL 2007003440 A CL2007003440 A CL 2007003440A CL 2007003440 A1 CL2007003440 A1 CL 2007003440A1
Authority
CL
Chile
Prior art keywords
obesida
desaturasa
coenzima
azacicloalcanos
estearoil
Prior art date
Application number
CL200703440A
Other languages
English (en)
Inventor
Nicolas Li Chun Sing Lachance
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of CL2007003440A1 publication Critical patent/CL2007003440A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
CL200703440A 2006-12-01 2007-11-29 Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida CL2007003440A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87221606P 2006-12-01 2006-12-01
US89890007P 2007-02-01 2007-02-01

Publications (1)

Publication Number Publication Date
CL2007003440A1 true CL2007003440A1 (es) 2008-04-04

Family

ID=39467388

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703440A CL2007003440A1 (es) 2006-12-01 2007-11-29 Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida

Country Status (24)

Country Link
US (1) US8063224B2 (es)
EP (1) EP2099793B1 (es)
JP (1) JP5050061B2 (es)
KR (1) KR20090086623A (es)
AR (1) AR064026A1 (es)
AT (1) ATE543816T1 (es)
AU (1) AU2007327276B2 (es)
BR (1) BRPI0719702A2 (es)
CA (1) CA2670703C (es)
CL (1) CL2007003440A1 (es)
CO (1) CO6190521A2 (es)
CR (1) CR10858A (es)
EA (1) EA200970524A1 (es)
EC (1) ECSP099375A (es)
GT (1) GT200900144A (es)
IL (1) IL198824A0 (es)
MA (1) MA31017B1 (es)
MX (1) MX2009005713A (es)
NO (1) NO20092469L (es)
PE (1) PE20081199A1 (es)
SV (1) SV2009003275A (es)
TN (1) TN2009000212A1 (es)
TW (1) TW200826936A (es)
WO (1) WO2008064474A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987001B2 (en) * 2000-02-24 2006-01-17 Xenon Pharmaceuticals Inc. Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
EP2027121A1 (en) * 2006-05-22 2009-02-25 Merck Frosst Canada Ltd. Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US20090170828A1 (en) * 2006-06-12 2009-07-02 Elise Isabel Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
AU2007260528A1 (en) 2006-06-13 2007-12-21 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2007283401A1 (en) * 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
WO2008128335A1 (en) * 2007-04-20 2008-10-30 Merck Frosst Canada Ltd. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2010527941A (ja) * 2007-05-23 2010-08-19 メルク フロスト カナダ リミテツド ステアロイル−補酵素ａデルタ−９デサチュラーゼの阻害剤としての二環式芳香族複素環化合物
US7842696B2 (en) 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
WO2009011451A1 (en) * 2007-07-19 2009-01-22 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
WO2009012573A1 (en) * 2007-07-20 2009-01-29 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2735794A1 (en) * 2008-09-08 2010-03-11 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2010215035B2 (en) * 2009-02-17 2014-06-12 Merck Canada Inc. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
EP2398796A4 (en) * 2009-02-23 2012-10-10 Merck Canada Inc HETEROCYCLIC DERIVATIVES AS INHIBITORS OF THE STEAROYL COENZYME A DELTA 9 DESATURASE
US20120010186A1 (en) * 2009-03-23 2012-01-12 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2459568A4 (en) 2009-07-28 2013-02-27 Merck Frosst Canada Ltd NOVEL SPIRO COMPOUNDS USEFUL AS DELTA-9 DEATURASE STEAROYL COENZYME INHIBITORS
ES2613066T3 (es) 2010-04-28 2017-05-22 Bayer Intellectual Property Gmbh Derivados de cetoheteroarilpiperidina y -piperazina como fungicidas
PT2668182T (pt) * 2011-01-28 2018-01-31 4Sc Discovery Gmbh Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
WO2013062882A1 (en) * 2011-10-26 2013-05-02 Merck Canada Inc. Scd inhibitors for the treatment of hcv
WO2013134546A1 (en) 2012-03-07 2013-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US9456998B2 (en) 2012-05-22 2016-10-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Selective inhibitors of undifferentiated cells
CN110099898B (zh) * 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
EA201991650A1 (ru) * 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1595923A1 (de) * 1965-02-20 1969-11-27 Merck Ag E 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung
CA2237273C (en) 1996-01-15 2009-01-13 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
US20050119251A1 (en) 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP2316826A1 (en) 2003-07-30 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutics agents
US7345043B2 (en) 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
EP1830837B1 (en) * 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CN101083986A (zh) 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
MX2007003325A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
AR051090A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR051094A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion
WO2006125181A2 (en) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Piperidine derivatives and their use as stearoyl-coa desaturase modulators
JP2008545760A (ja) 2005-06-09 2008-12-18 メルク フロスト カナダ リミテツド ステアロイル−コエンザイムａデルタ−９デサチュラーゼのインヒビターとしてのアザシクロヘキサン誘導体
JP2009501733A (ja) 2005-07-20 2009-01-22 メルク フロスト カナダ リミテツド ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのヘテロ芳香族化合物
WO2007038865A1 (en) 2005-10-05 2007-04-12 Merck Frosst Canada Ltd. Substituted quinolines as inhibitors of leukotriene biosynthesis
AU2006315025A1 (en) 2005-11-15 2007-05-24 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US7799787B2 (en) 2005-12-20 2010-09-21 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2027121A1 (en) 2006-05-22 2009-02-25 Merck Frosst Canada Ltd. Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US20090170828A1 (en) 2006-06-12 2009-07-02 Elise Isabel Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
AU2007260528A1 (en) 2006-06-13 2007-12-21 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2007283401A1 (en) 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
WO2008046226A1 (en) 2006-10-20 2008-04-24 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa

Also Published As

Publication number Publication date
BRPI0719702A2 (pt) 2013-12-17
CR10858A (es) 2009-06-25
CA2670703C (en) 2012-05-15
AU2007327276B2 (en) 2011-06-09
KR20090086623A (ko) 2009-08-13
JP2010510993A (ja) 2010-04-08
PE20081199A1 (es) 2008-10-19
TN2009000212A1 (en) 2010-10-18
AU2007327276A1 (en) 2008-06-05
GT200900144A (es) 2011-06-23
EP2099793A1 (en) 2009-09-16
JP5050061B2 (ja) 2012-10-17
IL198824A0 (en) 2010-02-17
CO6190521A2 (es) 2010-08-19
SV2009003275A (es) 2009-11-18
AR064026A1 (es) 2009-03-04
EP2099793B1 (en) 2012-02-01
US20080132542A1 (en) 2008-06-05
MA31017B1 (fr) 2009-12-01
ECSP099375A (es) 2009-07-31
TW200826936A (en) 2008-07-01
NO20092469L (no) 2009-08-27
US8063224B2 (en) 2011-11-22
EP2099793A4 (en) 2010-12-29
MX2009005713A (es) 2009-06-08
WO2008064474A1 (en) 2008-06-05
ATE543816T1 (de) 2012-02-15
EA200970524A1 (ru) 2009-12-30
CA2670703A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2007003733A1 (es) Compuestos derivados de indolin-2-ona, bencimidazol-2-ona y benzoxazol-2-ona, moduladores de serina palmitoiltransferasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 1 y 2, obesidad, aterosclerosis, hi
CL2007003614A1 (es) Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
CL2007003262A1 (es) Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades.
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
CL2007003261A1 (es) Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, tales como esquizofrenia,
CL2007001778A1 (es) Compuestos derivados de 2-pirazinacarboxamida, antagonistas/agonistas inversos selectivos de cb1; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de ingestion de comida, diabetes tipo ii y a
CL2007002099A1 (es) Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma.
CL2008001125A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2008000531A1 (es) Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda
CL2008001126A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2008000180A1 (es) Sal tosilato de trans-n-etil-3-fluoro-3-[3-fluoro-4-(pirrolidin-1-ilmetil)fenil]ciclobutanocarboxamida; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como depresion, trastornos del sueno, ansiedad y enfermedades del tracto
CL2007001887A1 (es) Compuestos derivados de bifensustuidas por tetrazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con los receptores purinergicos de p2x, tales como trastornos gastrointes
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2007003502A1 (es) Compuestos derivados de pirimidin-amina, moduladores de jnk; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento de artritis reumatoide, asma, diabetes tipo ii, enfermedad de alzheimer, enfermedad de parkinson y apoplejia.
BRPI0808293A2 (pt) "composições para administração nasal"
BRPI0810390A2 (pt) Película, composição, e, métodos para administrar um material ativo, para melhorar a estabilidade de uma película e para manter a saúde sistêmica de um mamífero
CL2007001006A1 (es) Compuestos derivados de piperidina u 8-aza-biciclo[3.2.1]octano sustituidos; formulacion farmaceutica; producto; y uso para el tratamiento o prevencion de enfermedades tales como diabetes mellitus no insulino dependiente, artritis, obesidad, dislipid